Statins in patients with chronic kidney disease: Evidence from systematic reviews and randomized clinical trials

PLoS Medicine

Volumn 3, Issue 5, 2006, Pages 615-618

  Navaneethan, Sankar D ^a   Pansini, Francesca ^b   Strippoli, Giovanni F M ^c  

^a UNITY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DIALYSIS; HEMODIALYSIS; HUMAN; KIDNEY GRAFT; MORTALITY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DRUG EFFECT; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CHRONIC DISEASE; DIALYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33744479151     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030123     Document Type: Review

References (21)

1. United States Renal Data System (2005) USRDS 2005 annual data report. Bethesda (Maryland): National Institute of Diabetes and Digestive and Kidney Diseases. Available: http://www.usrds.org/adr.htm. Accessed 14 March 2006.
2. Cheung AK, Wu LL, Kablitz C, Leypoldt JK (1993) Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 22: 271-276.
3. Iseki K, Yamazato M, Tozawa M, Takishita S (2002) Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61: 1887-1893.
4. Flieshmann EH, Bower JD, Salahudeen AK (2001) Risk factor paradox in hemodialysis: Better nutrition as a partial explanation. ASAIO J 47: 74-81.
5. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, et al. (2002) HMG CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61: 297-304.
6. Mason NA, Bailie GR, Satayathum S (2005) HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45: 119-126.
7. Kidney Disease Outcomes Quality Initiative Group (2003) K/DOQI guidelines for management of dyslipidemias in patients with chronic kidney disease. Am J Kidney Dis 41: S1-S91.
8. Grassmann A, Gioberge S, Moller S, Brown G (2005) ESRD patients in 2004: Global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 20: 2587-2593.
9. Navaneethan SD, Shrivastava R (2004) HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 18: CD004289.
10. Lentine KL, Brennan DC (2004) Statin use after renal transplantation: A systematic quality review of trial-based evidence. Nephrol Dial Transplant 19: 2378-2386.
11. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, et al. (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248.
12. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, et al. (2005) First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45: 473-484.
13. Tonelli M, Moye L, Sacks FM, Cole T, Curham GC (2003) Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605-1613.
14. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, et al. (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 21: 1557-1563.
15. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, et al. (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet. 14: 2024-2031.
16. Baigent C, Landry M (2003) Study of heart and renal protection (SHARP). Kidney Int Suppl 2003: S207-S210.
17. Diepeveen SH, Verhoeven GW, Van Der Palen J, Dikkeschei LD, Van Tits LJ, et al. (2005) Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: A randomised-controlled trial. J Intern Med 257: 438-445.
18. Harris KP, Wheeler DC, Chong CC, Atorvastatin in CAPD Study Investigators (2002) A placebo controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 61: 1469-1474.
19. Lins RL, Matthys KE, Billiouw JM, Dratwa M, Dupont P, et al. (2004) Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: A placebo-controlled study. Clin Nephrol 62: 287-294.
20. Walker RJ, Sutherland WH, Walker HL, MaMahon S, Robson RA (1997) Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrol Dial Transplant 12: 87-92.
21. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J (2002) Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 39: 283-290.